TrialAnnals of oncology : official journal of the European Society for Medical Oncology2025

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.

C Gratzke et al.PubMed ↗Publisher ↗

No numbers read from the abstract.